DexCom Inc. — 6.9/10 — $62.22

DexCom is the second-largest global continuous glucose monitoring (CGM) company, operating in a duopoly with Abbott that together controls approximately 91% of the CGM market (Abbott ~56%, DexCom ~35%, Medtronic ~7%). The oligopoly quality gate PASSES -- the combined two-player share exceeds 90%, creating structural pricing power and barriers to entry. DexCom designs and manufactures wearable CGM sensors that continuously track glucose levels, primarily for people with diabetes.

The penetration runway is massive and arguably the single most important investment thesis element. Type 1 diabetes CGM penetration is approximately 30%. Type 2 insulin-dependent penetration is below 5%. Type 2 non-insulin penetration is below 1%. The global diabetic population is projected to reach 643 million by 2030, with the total addressable market expanding from $13.3B to $31B+ by 2031 (15% CAGR). GLP-1 medications are a tailwind, not a headwind -- CGM adoption is 4x higher among GLP-1 users, and 100% of surveyed HCPs recommend the combination.

FY2025 marked a revenue recovery after the Q2 2024 crisis. Revenue reached $4.63B (+15.6% YoY) after bottoming at +2% in Q3 2024 when US growth went negative. The recovery was driven by G7 sensor uptake, Stelo OTC launch ($130M first year, 500K+ users), and international expansion. Non-GAAP gross margin troughed at 57.5% in Q1 2025 due to supply chain issues (damaged shipments, freight/scrap) before recovering to 63.5% by Q4. Q4 non-GAAP operating margin hit a record 26.3%. FCF surged 71% to $1.08B, crossing the $1B threshold for the first time.

The Q2 2024 guide-down remains the defining credibility event. Management cut guidance by approximately $250M due to a botched salesforce expansion -- a self-inflicted wound that shattered investor trust. Six consecutive quarters of recovery (3% to 20% growth) and consistent beat-and-raise execution have partially rebuilt credibility, but the stock continues to exhibit a beat-and-sell pattern (4+ consecutive beats, stock falls each time). CEO Kevin Sayer departed at end 2025 (medical leave), replaced by Teri Leach, a 20-year insider and former CTO who is technically strong but unproven as a public company CEO.

DXCM receives a composite score of 6.9/10, reflecting a CGM duopoly with the most compelling penetration runway in medical devices, offset by a still-unhealed Q2 2024 trust deficit, a fresh CEO transition, and an entrenched beat-and-sell pattern that keeps the stock pinned near 52-week lows despite strong fundamental recovery.

Bull case ($90-110): Medicare T2NI coverage is approved (CMS proposal H1 2026, implementation 2027), unlocking ~12M beneficiaries and re-rating the stock. G7 15-day sensor drives margin expansion internationally. Stelo OTC scales beyond $250M and opens the general wellness category. GLP-1 narrative shifts from headwind fear to confirmed tailwind (4x CGM adoption among users). New CEO Leach delivers a clean first earnings call and Investor Day (May 2026) provides a credible long-term framework. Stock re-rates toward 30-35x forward earnings on renewed growth visibility.

Base case ($65-85): Revenue grows 11-13% in line with guidance. Margins continue gradual improvement but GM remains below the 64-65% target that was missed in 2025. Medicare T2NI coverage is proposed but implementation slips to 2028. Abbott continues gaining international share. Beat-and-sell pattern persists as buy-side remains skeptical. Analyst targets of $87-102 are partially achieved. The stock grinds higher from lows but without a catalyst to break the pattern.

Bear case ($40-55): Medicare T2NI coverage is delayed or denied, removing the key catalyst. Abbott Libre gains meaningful share with its $7.6B CGM franchise (+17% growth). FDA warning letter (G7 adulterated classification) escalates to manufacturing disruption. New CEO stumbles on first earnings call or strategic pivot. Revenue growth decelerates below 10% as the post-Q2 2024 recovery normalizes. Multiple compresses toward 20x on reduced growth expectations.

Bottom line: DexCom operates in one of the strongest duopolies in healthcare with a penetration runway that could sustain double-digit growth for a decade. The 6.9 score reflects excellent thematic positioning (8/10) and strong financial recovery (7/10) dragged down by management credibility damage (6/10) from the Q2 2024 guide-down and an unproven new CEO. At 25x forward P/E near 52-week lows with a 40-60% analyst-price gap, this is a speculative watchlist name where the Medicare T2NI catalyst could be transformative -- but the trust deficit must heal first.

Key catalysts and monitoring points:

• Medicare T2NI coverage timeline: The single most important catalyst. CMS proposal expected H1 2026, implementation potentially 2027. Would unlock approximately 12 million Medicare beneficiaries with Type 2 non-insulin diabetes. Not included in 2026 guidance, representing pure upside.
• New CEO Teri Leach -- first earnings call: Leach replaced Sayer (who departed end 2025 on medical leave). She is a 20-year insider and former CTO, technically strong but unproven as a public company CEO. Her first earnings call and Investor Day (May 2026) will set the tone for whether investor trust can rebuild.
• Beat-and-sell pattern: DexCom has beaten estimates for 4+ consecutive quarters, yet the stock has fallen each time. This pattern reflects deep buy-side skepticism from the Q2 2024 guide-down. Breaking this pattern requires either a blowout quarter or a structural catalyst (Medicare T2NI).
• FDA warning letter resolution: The G7 received an adulterated classification from the FDA. Class action lawsuits have followed. Monitor for resolution or escalation -- manufacturing disruption would be material.
• Abbott competitive dynamics: Abbott Libre is a $7.6B franchise growing 17%, gaining share particularly internationally. Monitor quarterly share trends and pricing dynamics, especially as Medicare coverage potentially expands the addressable market.
• Gross margin trajectory: Non-GAAP GM was guided to 64-65% but delivered ~61% due to supply chain issues. Recovered to 63.5% by Q4 2025. Track whether the 64-65% target is achievable in 2026 -- this is a key indicator of operational execution under new leadership.
• Stelo OTC scaling: $130M first year with 500K+ users. Monitor whether the OTC wellness channel can scale to $250M+ and whether it cannibalize prescription CGM or expands the overall market.
• GLP-1 adoption data: The narrative has shifted from headwind to tailwind (4x CGM adoption among GLP-1 users). Watch for continued real-world data confirming this relationship.
• Next earnings: Late April / May 2026. Key focus on revenue trajectory vs 11-13% guide, GM recovery, and new CEO messaging.

For the full analysis, see the Business Model, Financials, and Valuation pages.

Speculative Watchlist -- DexCom is a CGM duopoly with the most compelling penetration runway in medical devices, trading near 52-week lows with a massive analyst-price gap, but the Q2 2024 trust deficit remains unhealed and the CEO transition adds uncertainty. The stock at $62.22 is down 31% from its 52-week high of $89.98 and only 15% above its 52-week low of $54.11, suggesting deep value potential but also reflecting genuine investor skepticism.

The fundamental picture is strong and improving: revenue recovered from +2% to +15.6%, FCF crossed $1B for the first time (+71%), Q4 operating margin hit a record 26.3%, and the penetration runway (Type 2 at less than 5%) could sustain double-digit growth for a decade. The duopoly structure (91% combined share) provides pricing power and barriers to entry. GLP-1 medications are a confirmed tailwind (4x CGM adoption). However, the Q2 2024 guide-down (~$250M self-inflicted cut) was a top-tier credibility event that continues to suppress the multiple, the new CEO is unproven, and the FDA warning letter adds risk.

What would change the recommendation up: (1) Medicare T2NI coverage is approved, unlocking ~12M beneficiaries and validating the penetration thesis. (2) New CEO Leach delivers a credible Investor Day framework (May 2026) that rebuilds institutional trust. (3) Beat-and-sell pattern breaks on a blowout quarter with upward guidance revision. (4) FDA warning letter is resolved without manufacturing impact. (5) Gross margins sustainably reach the 64-65% target.

What would change the recommendation down: (1) Medicare T2NI coverage is denied or delayed beyond 2028, removing the key catalyst. (2) Abbott gains meaningful share in the US (currently concentrated internationally). (3) FDA warning letter escalates to manufacturing disruption or product recall. (4) Revenue growth decelerates below 10% as the post-crisis recovery normalizes. (5) New CEO makes strategic missteps or fails to articulate a coherent long-term vision.